Wang Xiao-Jing, Yan Wei-Ming, Zhang Jiang-Guo, Wang Hong-Wu, Zou Yong, Luo Xiao-Ping, Ning Qin
Institute of Infectious Disease, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Zhonghua Gan Zang Bing Za Zhi. 2009 Mar;17(3):180-3.
To investigate role of CD4-CD8- T cells in murine hepatitis virus type 3 (MHV-3) induced chronic viral hepatitis in C3H/Hej mice and to identify their surface markers.
Thirty C3H/Hej mice received 10 Pfu MHV-3 intraperitoneally, the CD4-CD8- T cells were isolated using magnetic bead sorting on 0, 4, 15, 30, 40 days post MHV-3 infection. The cytotoxic effects of CD4-CD8- T cells on normal and infected hepatocytes, CD8+ T cells and unrelated-virus (murine cytomegalovirus, MCMV) infected CD8+ T cells were examined by non-radioactive cytotoxicity assay. The surface markers of CD4-CD8- T cells were determined by flow cytometry.
MHV-3 infected CD4-CD8- T cells showed significant cytotoxic effect on CD8+ T cells, but not on infected hepatocytes or MCMV infected CD8+ T cells. The analysis of cell surface markers demonstrated that the CD4-CD8- T cells are a completely new T cell subset.
CD4-CD8- T cells have significant cytotoxic effect on virus specific CD8+ T cells in MHV-3 infected C3H/Hej mice, which suggests that CD4-CD8- T cells have immune modulatory functions in the development of chronic viral hepatitis. The phenotype of these CD4-CD8- T cells detected by flow cytometry is TCR alpha beta +CD3+CD4- CD8- CD25- CD28- CD30- CD44+.
研究CD4-CD8-T细胞在3型鼠肝炎病毒(MHV-3)诱导的C3H/Hej小鼠慢性病毒性肝炎中的作用,并鉴定其表面标志物。
30只C3H/Hej小鼠腹腔注射10个噬斑形成单位(Pfu)的MHV-3,在MHV-3感染后的0、4、15、30、40天,使用磁珠分选法分离CD4-CD8-T细胞。通过非放射性细胞毒性试验检测CD4-CD8-T细胞对正常和感染的肝细胞、CD8+T细胞以及无关病毒(鼠巨细胞病毒,MCMV)感染的CD8+T细胞的细胞毒性作用。通过流式细胞术测定CD4-CD8-T细胞的表面标志物。
MHV-3感染的CD4-CD8-T细胞对CD8+T细胞显示出显著的细胞毒性作用,但对感染的肝细胞或MCMV感染的CD8+T细胞无此作用。细胞表面标志物分析表明,CD4-CD8-T细胞是一个全新的T细胞亚群。
在MHV-3感染的C3H/Hej小鼠中,CD4-CD8-T细胞对病毒特异性CD8+T细胞具有显著的细胞毒性作用,这表明CD4-CD8-T细胞在慢性病毒性肝炎的发展中具有免疫调节功能。通过流式细胞术检测到的这些CD4-CD8-T细胞的表型为TCRαβ+CD3+CD4-CD8-CD25-CD28-CD30-CD44+。